About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Dual-tracer PET Radiomics for Prostate Cancer Stratification

NCT07655648·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Xiangya Hospital of Central South University

Age

Any age

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Treatment-naïve prostate cancer with subsequent radical prostatectomy (RP)
Availability of presurgical dual-tracer PET/CT images, biopsy, and RP pathology data

You may not be if

Unavailability of imaging or pathological data
PET/CT performed after any prostate cancer-related treatment
Interval between PET and biopsy \> 3 months
Interval between biopsy and RP \> 1 month

The record

StatusCompleted

PhaseNo phase

Taking part100

StartedJan 2020

UpdatedJun 18, 2026

Conditions

Prostate Cancer Gleason Score PET/CT Radiomics Biochemical Recurrence

Where1

Department of Nuclear Medicine, Xiangya Hospital, Central South University
Changsha, Hunan, China

Clareo Health | Dual-tracer PET Radiomics for Prostate Cancer Stratification